GLAXF - Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

2024-04-23 11:37:17 ET

Summary

• Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating landmark data with multi-bagger potential.
• Spero has excellent downside protection and additional upside from the payments from the Tebipenem HBr deal with GSK.
• Spero's significant undervaluation and potential path forward are highlighted in the peer comparison.

Overall, Spero Therapeutics, Inc. ( SPRO ) is on track for success and its three pipeline assets are progressing step by step. Based on the SPA agreement with the FDA, the first patients in the second Phase 3 trial for Tebipenem HBr in cUTI was enrolled at the end of 2023 and the data readout is expected in mid-2025. SPR720 is on track to report data from its pivotal Phase 2 proof-of-concept study in the second half of 2024. And for SPR206, the FDA has given the green light by confirming the IND to proceed with the Phase 2 trial, which can now be initiated subject to third-party funding.

The announcement by competitor AN2 Therapeutics ( ANTX ) to voluntarily suspend patient enrollment in the trial is another very positive development for Spero. However, all these developments have not failed to impact Spero's share price. Therefore, I will take this opportunity to take a look at the developments of the last couple of months and the outlook for the future....

For further details see: